List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
A new preclinical study has combined two experimental drugs that effectively block ovarian tumour growth – a strategy that could lead to new treatments against this genetically complex cancer.
Researchers at the University of Basel and Roche have discovered that slowing the intracellular transport of RNA-based drugs significantly improves their therapeutic impact.
9 July 2025 | By Eurofins Discovery
Safety data is no longer just a regulatory checkbox - it’s a strategic advantage. Discover how in vitro and computational tools reduce the reliance on animal testing and support smarter, earlier decision-making in drug discovery.
Using GenAI and expert reasoning, drug developers can now explore an asset’s long-term potential as early as the preclinical stage. This shift is helping to reshape pipeline planning and refine therapeutic strategy.
Researchers at the University of Oklahoma have found a way to improve drugs by adding just one carbon atom. This simple change could speed up drug discovery and lower costs.
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
See how the new Shasta™ Single Cell System enabled high-throughput single-cell DNA-seq library preparation to detect tumor-driving mutations.
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
11 April 2025 | By Drug Target Review
AI in drug discovery is no longer theoretical. It’s already speeding up target identification, improving predictions, and cutting waste. Learn how to apply it in your own discovery pipeline.
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
New research, led by USC Stem Cell scientists, has identified key genetic barriers to sensory cell regeneration in the ear and eye, paving the way for future drug therapies to restore hearing and vision.
4 April 2025 | By Eurofins Discovery
Dr. Francisca Neethling from Eurofins Discovery explores the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
28 March 2025 | By Drug Target Review
Manual processes are slowing down your lab. AI and automation can change that, if you know how to use them. In this free webinar, Dr Raminderpal Singh breaks down the technologies, data strategies and tools transforming early drug discovery, so you can stop guessing and start innovating.
